-
1
-
-
41349116947
-
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
-
Koren E., Smith H.W., Shores E., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Meth. 2008, 333:1-9.
-
(2008)
J. Immunol. Meth.
, vol.333
, pp. 1-9
-
-
Koren, E.1
Smith, H.W.2
Shores, E.3
-
2
-
-
67349241946
-
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
-
Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., et al. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 2009, 54:164-182.
-
(2009)
Regul. Toxicol. Pharmacol.
, vol.54
, pp. 164-182
-
-
Ponce, R.1
Abad, L.2
Amaravadi, L.3
Gelzleichter, T.4
Gore, E.5
-
3
-
-
71749108118
-
Foundation review: nonclinical development of biopharmaceuticals
-
23/24
-
Baumann A. Foundation review: nonclinical development of biopharmaceuticals. Drug Discov. Today 2009, 14:1112-1122. 23/24.
-
(2009)
Drug Discov. Today
, vol.14
, pp. 1112-1122
-
-
Baumann, A.1
-
4
-
-
0037075272
-
Pure red cell aplasia and anti-erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin
-
Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red cell aplasia and anti-erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin. New Engl. J. Med. 2002, 346:469-475.
-
(2002)
New Engl. J. Med.
, vol.346
, pp. 469-475
-
-
Casadevall, N.1
Nataf, J.2
Viron, B.3
Kolta, A.4
Kiladjian, J.J.5
Martin-Dupont, P.6
Michaud, P.7
Papo, T.8
Ugo, V.9
Teyssandier, I.10
Varet, B.11
Mayeux, P.12
-
5
-
-
9644287732
-
A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 1 - considering consequences of the immune response to a protein
-
Rosenberg A.S., Worobec A A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 1 - considering consequences of the immune response to a protein. Biopharm. Int. 2004, 17:22-26.
-
(2004)
Biopharm. Int.
, vol.17
, pp. 22-26
-
-
Rosenberg, A.S.1
Worobec, A.2
-
6
-
-
10944231251
-
A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 2 - considering host-specific and product specific factors impacting immunogenicity
-
Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 2 - considering host-specific and product specific factors impacting immunogenicity. Biopharm. Int. 2004, 17:34-42.
-
(2004)
Biopharm. Int.
, vol.17
, pp. 34-42
-
-
Rosenberg, A.S.1
Worobec, A.2
-
7
-
-
16844367771
-
A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 3 - effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies
-
Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 3 - effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. Biopharm. Int. 2005, 18:32-36.
-
(2005)
Biopharm. Int.
, vol.18
, pp. 32-36
-
-
Rosenberg, A.S.1
Worobec, A.2
-
8
-
-
34249684926
-
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
-
Shankar G., Pendley C., Stein K.E., et al. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 2007, 25:555-561.
-
(2007)
Nat. Biotechnol.
, vol.25
, pp. 555-561
-
-
Shankar, G.1
Pendley, C.2
Stein, K.E.3
-
10
-
-
78650769820
-
Evaluation of immunogenicity for pre-clinical and clinical investigations
-
Biopharm Knowledge Publishing, Westminister, London, N. Lyscom (Ed.)
-
Caras I. Evaluation of immunogenicity for pre-clinical and clinical investigations. Immunogenicity to Biologics 2007, Biopharm Knowledge Publishing, Westminister, London. N. Lyscom (Ed.).
-
(2007)
Immunogenicity to Biologics
-
-
Caras, I.1
-
11
-
-
65649090964
-
Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study
-
Loyet K.M., Deng R., Liang W.C., Wu Y., Lowman H.B., DeForge L.E. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J. Immunol. Methods 2009, 345:17.
-
(2009)
J. Immunol. Methods
, vol.345
, pp. 17
-
-
Loyet, K.M.1
Deng, R.2
Liang, W.C.3
Wu, Y.4
Lowman, H.B.5
DeForge, L.E.6
-
12
-
-
33746889823
-
A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection
-
Lu Y., Wong W.L., Meng Y.G. A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection. J. Immunol. Methods 2006, 314:74.
-
(2006)
J. Immunol. Methods
, vol.314
, pp. 74
-
-
Lu, Y.1
Wong, W.L.2
Meng, Y.G.3
-
13
-
-
3343015039
-
The role of the CD40 pathway in the pathogenesis and treatment of cancer
-
Eliopoulos A.G., Young L.S. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 2004, 4:360-367.
-
(2004)
Curr. Opin. Pharmacol.
, vol.4
, pp. 360-367
-
-
Eliopoulos, A.G.1
Young, L.S.2
-
14
-
-
0037277480
-
Prospects for CD40-directed experimental therapy of human cancer
-
Tong A.W., Stone M.J. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003, 10:1-13.
-
(2003)
Cancer Gene Ther.
, vol.10
, pp. 1-13
-
-
Tong, A.W.1
Stone, M.J.2
-
15
-
-
0035397985
-
Phase I study of recombinant human CD40 ligand in cancer patients
-
Vonderheide R.H., Dutcher J.P., Anderson J.E., Eckhardt S.G., Stephans K.F., Razvillas B., et al. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 2001, 19:3280-3287.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 3280-3287
-
-
Vonderheide, R.H.1
Dutcher, J.P.2
Anderson, J.E.3
Eckhardt, S.G.4
Stephans, K.F.5
Razvillas, B.6
-
16
-
-
33947506186
-
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
-
Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., Running, Huhn R.D., Antonia S.J., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007, 25:876-883.
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 876-883
-
-
Vonderheide, R.H.1
Flaherty, K.T.2
Khalil, M.3
Stumacher, M.S.4
Bajor, D.L.5
Hutnick, N.A.6
Running7
Huhn, R.D.8
Antonia, S.J.9
-
17
-
-
33747619436
-
Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870,893
-
Baltrukonis D.J., Finco-Kent D., Kawabata T.T., Poirier M., LeSauteur L. Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870,893. J. Immunotoxicol. 2006, 3:157-164.
-
(2006)
J. Immunotoxicol.
, vol.3
, pp. 157-164
-
-
Baltrukonis, D.J.1
Finco-Kent, D.2
Kawabata, T.T.3
Poirier, M.4
LeSauteur, L.5
-
18
-
-
35348909044
-
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
-
Wenzel S., Wilbraham D., Fuller R., Burmeister Getz E., Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-1431.
-
(2007)
Lancet
, vol.370
, pp. 1422-1431
-
-
Wenzel, S.1
Wilbraham, D.2
Fuller, R.3
Burmeister Getz, E.4
Longphre, M.5
-
19
-
-
0038517976
-
Interleukin-4 and interluekin-13 signaling connections maps
-
Kelly-Welch A.E., Hanson E.M., Boothby M.R., Keegan A.D. Interleukin-4 and interluekin-13 signaling connections maps. Science 2003, 300:1527-1528.
-
(2003)
Science
, vol.300
, pp. 1527-1528
-
-
Kelly-Welch, A.E.1
Hanson, E.M.2
Boothby, M.R.3
Keegan, A.D.4
-
20
-
-
3142534409
-
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
-
Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Meth. 2004, 289:1-16.
-
(2004)
J. Immunol. Meth.
, vol.289
, pp. 1-16
-
-
Mire-Sluis, A.R.1
Barrett, Y.C.2
Devanarayan, V.3
Koren, E.4
Liu, H.5
Maia, M.6
-
21
-
-
33745947584
-
Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo
-
Cox C.M., D'Agostino S.L., Miller M.K., Heimark R.L., Krieg P.A. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev. Biol. 2006, 296:177-189.
-
(2006)
Dev. Biol.
, vol.296
, pp. 177-189
-
-
Cox, C.M.1
D'Agostino, S.L.2
Miller, M.K.3
Heimark, R.L.4
Krieg, P.A.5
-
22
-
-
0142011150
-
Angiogenic and angiostatic factors in the molecular control of angiogenesis
-
Distler J.H., et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q. J. Nucl. Med. 2003, 47:149-161.
-
(2003)
Q. J. Nucl. Med.
, vol.47
, pp. 149-161
-
-
Distler, J.H.1
|